William J. Sandborn, M.D.

Photo of William Sandborn J., M.D.
William J. Sandborn, M.D.

Primary Appt:
Gastroenterology

Professor of Medicine
College of Medicine

Summary of current work

Significance of Research

  • To develop new and improved therapies for the treatment of ulcerative colitis, Crohn's disease, and pouchitis
  • To test new therapies for ulcerative colitis and Crohn's disease in clinical trials, leading to change in clincal practice and approval of new medications by the FDA.
Research Interests
  • Clinical trials of new medications for inflammatory bowel disease (azathioprine, 6-mercaptopurine, cyclosporine, tacrolimus, methotrexate, infliximab, CDP571, nicotine, etc.)
  • Clinical pharmacology of medications used in inflammatory bowel disease (Asacol, Pentasa, sulfasalazine, balsalazide, cyclosporine, azathioprine, 6-mercaptopurine, methotrexate, nicotine, etc.)
  • Classification, diagnosis and treatment of pouchitis following ileoanal pouch surgery for ulcerative colitis.
  • Epidemiology and pharmacoeconomics of inflammatory bowel disease.
  • Assessment of diagnostic tests for inflammatory bowel disease (diagnostic antibodies, stool markers of inflammation, etc.)

Specific Projects

  • Sandborn WJ, Tremaine WJ, Pike MJ, Mays DC, Lipsky JJ. A phase I study to determine the optimum dose and dosing schedule of intravenous azathioprine loading to decrease the time to response in in-patients with active, steroid-refractory ulcerative colitis. Principal Investigator
  • Sandborn WJ, Tremaine WJ, Loftus EV. A phase II, multi-national, double-blind, placebo-controlled parallel group study to assess the safety and potential of the engineered human anti-TNFa antibody, CDP571, to treat patients with moderate to severe Crohn's disease following an intravenous dose of 20 or 10 mg/kg of CDP571 followed by 8- or 12-weekly dosing with 10 mg/kg CDP571 over 24 weeks. Site Principal Investigator and Global North American Principal Investigator.
  • Sandborn WJ, Tremaine WJ, Loftus EV. A phase II, multi-national, double-blind, placebo-controlled parallel group, 16 week study to assess the safety and potential of the engineered human anti-TNFa antibody, CDP571, to prevent disease flare whilst allowing steroid withdrawal in steroid dependent patients with Crohn's disease following an intravenous dose of 20 mg/kg and then, 8 weeks later, 10 mg/kg of CDP571. Site Principal Investigator and Global North American Principal Investigator
  • Sandborn WJ, Loftus EV, Tremaine WJ, Homberger HA, Zinsmeister AR, Targan SR, Colombel JF, Seibold F, Chapman RW, Fleming KA. Evaluation of ANCA, ASCA, and APA as serologic disease markers in a population based cohort of patients with ulcerative colitis and Crohn's disease. Principal Investigator.
  • Lowry PW, Sandborn WJ, Mays DC, Lipsky JJ, Weinshilboum RM, Tremaine WJ, Zinsmeister AR, Pike MG, Otterness D, Szumlanski C. A pharmacodynamic and pharmacokinetic study to determine the clinical significance of drug interactions between azathioprine and sulfasalazine or Pentasa in patients with inflammatory bowel disease. Principal Investigator
  • Lowry PW, Sandborn WJ, Mays DC, Lipsky JJ, Weinshilboum RM, Tremaine WJ, Zinsmeister AR, Pike MG. A cross-sectional study of inflammatory bowel disease patients receiving azathioprine or 6-mercaptopurine to determine the relationship between thiopurine methyltransferase activity, 6-thioguanine nucleotide concentration, and disease status including leukopenia. Principal Investigator
  • Sandborn WJ, Tremaine WJ, Loftus EV, Panaccione R. A randomized, double-masked, placebo-controlled trial of three intravenous regimens of ISIS 2302 (2 mg/kg q.d. times 1, 3, and 5) in steroid-dependent Crohn's disease. Principal Investigator
  • Panaccione R, Sandborn WJ, Tremaine WJ, Loftus EV, Perrault J, Zinsmeister AR. Prevalence of extraintestinal manifestations and autoimmune disorders in patients with familial and sporadic inflammatory bowel disease. Principal Investigator
  • Sandborn WJ. A randomized, double-blind, placebo-controlled, multicenter trial of oral tacrolimus (FK-506) in the treatment of Crohn's disease complicated by enterocutaneous fistulae. Principal Investigator

Technologies Used

  • Development of delayed-release oral and rectal delivery systems for medications relevant to the treatment of ulcerative colitis and Crohn's disease, with the goal of enhancing efficacy and decreasing toxicity.
  • Therapeutic drug monitoring with high performance liquid chromatography for cyclosporine, tacrolimus, azathioprine and 6-mercaptopurine, and methotrexate.

Recent publications

See my publications on PubMed

Education

Fellowship – Gastroenterology
Mayo Clinic College of Medicine

Residency – Internal Medicine
Loma Linda University Medical Center

M.D.
Loma Linda University School of Medicine

B.A. – Chemistry
Southern College




Appointments Contact Us Make A Gift Search